SAA1 and familial pancreatic carcinoma: Clinically, elevated circulating SAA levels have been correlated with poor prognosis in various cancers, including lung and pancreatic cancer, reinforcing its potential role as a prognostic biomarker for immunotherapy resistance (15, 32, 39–41).